NORTH CHICAGO, Ill. and SOUTH SAN FRANCISCO, Calif., April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV)  and CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that they have entered into a collaboration to co-develop and co-commercialize Probody™ Drug Conjugates against CD71, also known as transferrin receptor 1 (TfR1). CD71 is highly expressed in a number of solid and hematologic cancers and has attractive molecular properties for efficient delivery of cytotoxic payloads to tumor cells. Probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

NORTH CHICAGO, Ill. and BREDA, The Netherlands and GHENT, Belgium, April 21, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, and argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases will collaborate to develop and commercialize ARGX-115. ARGX-115 is argenx' preclinical-stage human antibody program targeting the novel immuno-oncology target GARP, a protein believed to contribute to immuno-suppressive effects of T-cells.

CHICAGO and NORTH CHICAGO, Ill., April 20, 2016 /PRNewswire/ -- The University of Chicago and AbbVie (NYSE: ABBV), a global biopharmaceutical company, have entered into a five-year collaboration agreement designed to improve the pace of discovery and advance medical research in oncology at both organizations.

NORTH CHICAGO, Ill., April 20, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Deutsche Bank 41st Annual Health Care Conference on Wednesday, May 4, 2016. Bill Chase, executive vice president and chief financial officer, will participate in a question and answer session at 9:40 a.m. Central time.

NORTH CHICAGO, Ill., April 11, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Venclexta™ (venetoclax) tablets for patients diagnosed with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA-approved test, who have received at least one prior therapy.1 The FDA approved this indication under accelerated approval based on overall response rate, and continued approval may be contingent upon verification and description of clinical benefit in a confirmatory trial. The FDA approved Venclexta as a first-in-class, oral, once-daily medicine1 that selectively inhibits the BCL-2 protein.1 The BCL-2 protein blocks apoptosis (programmed cell death) of cells, including some cancer cells, and can be overexpressed in CLL cells.1 Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group. It is marketed collaboratively by the companies in the U.S. and by AbbVie outside of the U.S.

NORTH CHICAGO, Ill., April 7, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2016 financial results on Thursday, April 28, 2016, before the market opens.

NORTH CHICAGO, Ill., April 6, 2016 /PRNewswire/ -- AbbVie today announced that the 2016 AbbVie CF Scholarship, which honors and supports young adults with cystic fibrosis (CF) as they pursue higher education, is now accepting applications. Undergraduate and graduate students can apply for the scholarship from now until May 27, 2016 at 10:00 a.m. U.S. central time by visiting

NORTH CHICAGO, Ill., April 5, 2016 /PRNewswire/ -- AbbVie today announced a partnership with celebrity dietitian Joy Bauer to raise awareness about the importance of a healthy diet and lifestyle for people with a little-known gastrointestinal (GI) condition called exocrine pancreatic insufficiency (EPI). The renowned dietitian and television personality drew upon the expertise from her 25-year career to develop a guide containing nutrition tips and healthy recipes for this community of patients. The nutrition guide, along with additional information on EPI can be found at

NORTH CHICAGO, Ill., April 4, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for HUMIRA® (adalimumab) for the treatment of moderately to severely active Crohn's disease in pediatric patients (from six years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.